Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 1
1994 1
1998 2
1999 1
2001 2
2002 1
2004 1
2005 3
2007 2
2008 1
2009 2
2010 6
2011 2
2012 2
2013 6
2014 3
2016 1
2017 2
2018 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Mesalazine-induced renal calculi.
Jacobsson H, Eriksen J, Karlén P. Jacobsson H, et al. Among authors: karlen p. Am J Case Rep. 2013 Dec 23;14:551-3. doi: 10.12659/AJCR.889719. eCollection 2013. Am J Case Rep. 2013. PMID: 24478817 Free PMC article.
[Colitis cancer--myth or reality?].
Hertervig E, Befrits R, Ekbom A, Karlén P, Lindberg J, Löfberg R, Rutegård J, Sjöqvist U, Ost A. Hertervig E, et al. Among authors: karlen p. Lakartidningen. 2009 Nov 4-12;106(45):3000-2. Lakartidningen. 2009. PMID: 19998826 Review. Swedish. No abstract available.
Naïve T cells in the gut: how to really find them?
Karlsson M, Linton L, Lampinen M, Karlén P, Glise H, Befrits R, Janczewska I, Carlson M, Winqvist O, Eberhardson M. Karlsson M, et al. Among authors: karlen p. Scand J Gastroenterol. 2014 Apr;49(4):518. doi: 10.3109/00365521.2014.884159. Epub 2014 Feb 3. Scand J Gastroenterol. 2014. PMID: 24484322 No abstract available.
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.
Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Gunnarsson J, Malmgren C, Delin J, Strid H, Sjöberg M, Öberg D, Bergemalm D, Hjortswang H, Halfvarson J; SWIBREG SVEAH Study Group. Eriksson C, et al. Among authors: karlen p. Therap Adv Gastroenterol. 2021 Jul 3;14:17562848211023386. doi: 10.1177/17562848211023386. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34276808 Free PMC article.
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D; GO SWIBREG study group, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J. Eriksson C, et al. Among authors: karlen p. Scand J Gastroenterol. 2021 Nov;56(11):1304-1311. doi: 10.1080/00365521.2021.1963466. Epub 2021 Aug 20. Scand J Gastroenterol. 2021. PMID: 34415803 Free article.
Evidence for immunosurveillance in intestinal premalignant lesions.
Karlsson M, Lindberg K, Karlén P, Ost A, Thörn M, Winqvist O, Eberhardson M. Karlsson M, et al. Among authors: karlen p. Scand J Immunol. 2010 May;71(5):362-8. doi: 10.1111/j.1365-3083.2010.02377.x. Scand J Immunol. 2010. PMID: 20500687 Free article.
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
Keshav S, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, Rácz I, Hetzel D, Nielsen OH, Vermeire S, Reinisch W, Karlén P, Schreiber S, Schall TJ, Bekker P; Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group. Keshav S, et al. Among authors: karlen p. PLoS One. 2013;8(3):e60094. doi: 10.1371/journal.pone.0060094. Epub 2013 Mar 20. PLoS One. 2013. PMID: 23527300 Free PMC article. Clinical Trial.
42 results